Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study - Takeaways - MDSpire

Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study

  • By

  • Isabel Leroux-Roels

  • Azhar Alhatemi

  • Magalie Caubet

  • Fien De Boever

  • Bertrand de Wergifosse

  • Mohamed El Idrissi

  • Guilherme S Ferreira

  • Bart Jacobs

  • Axel Lambert

  • Sandra Morel

  • Charlotte Servais

  • Juan Pablo Yarzabal

  • October 24, 2024

  • 0 min

Share

  • 1

    The study evaluated the safety and immune response of a Clostridioides difficile vaccine candidate in healthy adults.

  • 2

    Subjects aged 18–45 received F2 antigen or placebo, while those aged 50–70 received F2 antigen with or without AS01 adjuvant.

  • 3

    Solicited adverse events were transient and more common in the adjuvanted group, but no serious adverse events were linked to the vaccine.

  • 4

    Immunogenicity was significantly higher in subjects receiving F2 antigen with AS01 compared to those receiving F2 antigen alone.

  • 5

    A third dose of the vaccine enhanced immune response in subjects with low baseline neutralization titers.

Original Source(s)

Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study

  • by Isabel Leroux-Roels, Azhar Alhatemi, Magalie Caubet, Fien De Boever, Bertrand de Wergifosse, Mohamed El Idrissi, Guilherme S Ferreira, Bart Jacobs, Axel Lambert, Sandra Morel, Charlotte Servais, Juan Pablo Yarzabal

  • October 24, 2024

Related Content

Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study

Defining Fulminant Clostridioides difficile Infections: Assessing the Utility of Hypotension as a Diagnostic Criterion

Risk Factors for Antibiotic Exposure Post–Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection: A Prospective Multicenter Observational Study